IL-17A抑制剂治疗银屑病和银屑病关节炎患者新发炎症性肠病的风险：一项基于人群的研究

IF 6.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Alimentary Pharmacology & Therapeutics Pub Date : 2025-04-07 DOI:10.1111/apt.70139

Saqr Alsakarneh, Omar Al Ta’ani, Razan Aburumman, Inas Mikhail, Jana G. Hashash, Francis A. Farraye

{"title":"IL-17A抑制剂治疗银屑病和银屑病关节炎患者新发炎症性肠病的风险：一项基于人群的研究","authors":"Saqr Alsakarneh, Omar Al Ta’ani, Razan Aburumman, Inas Mikhail, Jana G. Hashash, Francis A. Farraye","doi":"10.1111/apt.70139","DOIUrl":null,"url":null,"abstract":"IL-17 inhibitors effectively treat psoriasis and psoriatic arthritis but may increase the risk of inflammatory bowel disease (IBD). We assessed their association with IBD compared to apremilast. Utilising the TriNetX database, we analysed patients with psoriasis or ankylosing spondylitis initiating IL-17 inhibitors or apremilast. We used propensity score matching and Cox models to estimate IBD risk. Among 13,216 matched patients per group, 142 developed IBD with IL-17 inhibitors versus 60 with apremilast (aHR = 2.50, 95% CI: 1.85–3.39). IL-17 inhibitors increase IBD risk, necessitating careful patient selection and monitoring.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"35 1","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL-17A Inhibitors: A Population-Based Study\",\"authors\":\"Saqr Alsakarneh, Omar Al Ta’ani, Razan Aburumman, Inas Mikhail, Jana G. Hashash, Francis A. Farraye\",\"doi\":\"10.1111/apt.70139\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"IL-17 inhibitors effectively treat psoriasis and psoriatic arthritis but may increase the risk of inflammatory bowel disease (IBD). We assessed their association with IBD compared to apremilast. Utilising the TriNetX database, we analysed patients with psoriasis or ankylosing spondylitis initiating IL-17 inhibitors or apremilast. We used propensity score matching and Cox models to estimate IBD risk. Among 13,216 matched patients per group, 142 developed IBD with IL-17 inhibitors versus 60 with apremilast (aHR = 2.50, 95% CI: 1.85–3.39). IL-17 inhibitors increase IBD risk, necessitating careful patient selection and monitoring.\",\"PeriodicalId\":121,\"journal\":{\"name\":\"Alimentary Pharmacology & Therapeutics\",\"volume\":\"35 1\",\"pages\":\"\"},\"PeriodicalIF\":6.6000,\"publicationDate\":\"2025-04-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alimentary Pharmacology & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/apt.70139\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alimentary Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/apt.70139","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

IL-17抑制剂有效治疗银屑病和银屑病关节炎，但可能增加炎症性肠病（IBD）的风险。我们评估了与阿普雷米司特相比，它们与IBD的关系。利用TriNetX数据库，我们分析了银屑病或强直性脊柱炎患者启动IL-17抑制剂或阿普米司特。我们使用倾向评分匹配和Cox模型来估计IBD风险。在每组13216例匹配的患者中，142例使用IL-17抑制剂，60例使用阿普米司特（aHR = 2.50, 95% CI: 1.85-3.39）。IL-17抑制剂增加IBD风险，需要仔细选择和监测患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL-17A Inhibitors: A Population-Based Study

查看原文本刊更多论文

Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL-17A Inhibitors: A Population-Based Study

IL-17 inhibitors effectively treat psoriasis and psoriatic arthritis but may increase the risk of inflammatory bowel disease (IBD). We assessed their association with IBD compared to apremilast. Utilising the TriNetX database, we analysed patients with psoriasis or ankylosing spondylitis initiating IL-17 inhibitors or apremilast. We used propensity score matching and Cox models to estimate IBD risk. Among 13,216 matched patients per group, 142 developed IBD with IL-17 inhibitors versus 60 with apremilast (aHR = 2.50, 95% CI: 1.85–3.39). IL-17 inhibitors increase IBD risk, necessitating careful patient selection and monitoring.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Alimentary Pharmacology & Therapeutics 医学-胃肠肝病学

CiteScore

15.60

自引率

7.90%

发文量

527

审稿时长

3-6 weeks

期刊介绍： Alimentary Pharmacology & Therapeutics is a global pharmacology journal focused on the impact of drugs on the human gastrointestinal and hepato-biliary systems. It covers a diverse range of topics, often with immediate clinical relevance to its readership.